CA3127624A1 - Anti-cd38 antibodies - Google Patents

Anti-cd38 antibodies Download PDF

Info

Publication number
CA3127624A1
CA3127624A1 CA3127624A CA3127624A CA3127624A1 CA 3127624 A1 CA3127624 A1 CA 3127624A1 CA 3127624 A CA3127624 A CA 3127624A CA 3127624 A CA3127624 A CA 3127624A CA 3127624 A1 CA3127624 A1 CA 3127624A1
Authority
CA
Canada
Prior art keywords
seq
sequence
domain
binding
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3127624A
Other languages
English (en)
French (fr)
Inventor
Erin WILLERT
Kathleen Ann ELIAS
Gregory Landes
Shweta SINGH
Wouter Korver
Andrew Walling DRAKE
Mary Haak-Frendscho
Vinay Bhaskar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of CA3127624A1 publication Critical patent/CA3127624A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Finish Polishing, Edge Sharpening, And Grinding By Specific Grinding Devices (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Gas Separation By Absorption (AREA)
CA3127624A 2019-01-23 2020-01-23 Anti-cd38 antibodies Pending CA3127624A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962795855P 2019-01-23 2019-01-23
US62/795,855 2019-01-23
PCT/US2020/014845 WO2020154540A1 (en) 2019-01-23 2020-01-23 Anti-cd38 antibodies

Publications (1)

Publication Number Publication Date
CA3127624A1 true CA3127624A1 (en) 2020-07-30

Family

ID=69740548

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3127624A Pending CA3127624A1 (en) 2019-01-23 2020-01-23 Anti-cd38 antibodies

Country Status (9)

Country Link
US (2) US11414496B2 (https=)
EP (1) EP3914358A1 (https=)
JP (2) JP2022518282A (https=)
CN (1) CN113710324B (https=)
AR (1) AR119677A1 (https=)
AU (1) AU2020211407A1 (https=)
CA (1) CA3127624A1 (https=)
TW (1) TWI863959B (https=)
WO (1) WO2020154540A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113454108B (zh) 2019-01-23 2025-02-14 米伦纽姆医药公司 包含去免疫化志贺菌毒素a亚基效应子的cd38结合蛋白
AR119677A1 (es) 2019-01-23 2022-01-05 Millennium Pharm Inc Dominios de unión anti-cd38
CA3180690A1 (en) * 2020-06-17 2021-12-23 Ahmed Mahiuddin Cd38 antibodies for treatment of human diseases
WO2023172983A1 (en) * 2022-03-08 2023-09-14 Molecular Templates, Inc. Ctla-4 binding molecules comprising shiga toxin a subunit scaffolds and uses thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
CZ295838B6 (cs) 1996-09-09 2005-11-16 Zealand Pharma A/S Způsob výroby peptidů
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP0915987A2 (en) 1997-04-21 1999-05-19 Donlar Corporation POLY-($g(a)-L-ASPARTIC ACID), POLY-($g(a)-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7449443B2 (en) 2000-03-23 2008-11-11 California Institute Of Technology Method for stabilization of proteins using non-natural amino acids
US6586207B2 (en) 2000-05-26 2003-07-01 California Institute Of Technology Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
US7139665B2 (en) 2002-02-27 2006-11-21 California Institute Of Technology Computational method for designing enzymes for incorporation of non natural amino acids into proteins
EA200401325A1 (ru) 2002-04-09 2005-04-28 Киова Хакко Когио Ко., Лтд. Клетки с модифицированным геномом
EP1675620B1 (en) 2003-10-09 2019-05-08 Ambrx, Inc. Polymer derivatives
EP2327724A3 (en) 2004-02-02 2011-07-27 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US7887801B2 (en) 2007-07-13 2011-02-15 Topotarget Germany Ag Optimized DNA and protein sequence of an antibody to improve quality and yield of bacterially expressed antibody fusion proteins
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
RS60280B1 (sr) 2013-03-12 2020-06-30 Molecular Templates Inc Citotoksični proteini koji sadrže ciljane vezujuće regione za ćelije i regioni shiga toksina a podjedinice za selektivno ubijanje određenih vrsta ćelija
ES2774976T3 (es) 2013-04-29 2020-07-23 Teva Pharmaceuticals Australia Pty Ltd Anticuerpos anti-CD38 y fusiones con interferón alfa-2b atenuado
US20160177284A1 (en) 2014-01-27 2016-06-23 Molecular Templates, Inc. Cell-targeted molecules comprising amino-terminus proximal or amino-terminal shiga toxin a subunit effector regions
CN111909278B (zh) 2014-01-27 2024-04-09 分子模板公司 Mhc i类表位递送多肽
WO2017019623A2 (en) 2015-07-26 2017-02-02 Molecular Templates, Inc. Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes
US9603927B2 (en) * 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
ES2723774T3 (es) 2014-03-11 2019-09-02 Molecular Templates Inc Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal
AU2015229583B2 (en) 2014-03-11 2020-07-09 Molecular Templates, Inc. Proteins comprising amino-terminal proximal Shiga toxin A Subunit effector regions and cell-targeting immunoglobulin-type binding regions
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
ES2919749T3 (es) 2014-06-11 2022-07-28 Molecular Templates Inc Moléculas dirigidas a células citotóxicas resistentes a la escisión por proteasa
CA2961439A1 (en) 2014-11-05 2016-05-12 Genentech, Inc. Anti-fgfr2/3 antibodies and methods using same
MX2017010072A (es) 2015-02-05 2017-11-09 Molecular Templates Inc Moleculas multivalentes que se enlazan a cd20, las cuales comprenden regiones efectoras de la subunidad a de la toxina shiga, y composiciones enriquecidas de las mismas.
AU2016271124C1 (en) * 2015-05-30 2020-05-14 Molecular Templates, Inc. De-immunized, Shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
SG11201903693QA (en) * 2016-11-01 2019-05-30 Genmab Bv Polypeptide variants and uses thereof
WO2018106895A1 (en) 2016-12-07 2018-06-14 Molecular Templates, Inc. Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
EP3573648B1 (en) 2017-01-25 2023-11-22 Molecular Templates, Inc. Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopes
US20200190138A1 (en) 2017-02-28 2020-06-18 Chugai Seiyaku Kabushiki Kaisha Protein purification with protein l
CN113454108B (zh) * 2019-01-23 2025-02-14 米伦纽姆医药公司 包含去免疫化志贺菌毒素a亚基效应子的cd38结合蛋白
AR119677A1 (es) 2019-01-23 2022-01-05 Millennium Pharm Inc Dominios de unión anti-cd38
CN115769181B (zh) 2021-04-23 2025-10-10 京东方科技集团股份有限公司 一种解锁控制方法、装置、电子设备和计算机可读存储介质

Also Published As

Publication number Publication date
CN113710324A (zh) 2021-11-26
US11414496B2 (en) 2022-08-16
US20230203186A1 (en) 2023-06-29
AU2020211407A1 (en) 2021-08-12
JP2025060876A (ja) 2025-04-10
TW202043281A (zh) 2020-12-01
US20200231696A1 (en) 2020-07-23
US12312411B2 (en) 2025-05-27
TWI863959B (zh) 2024-12-01
AR119677A1 (es) 2022-01-05
CN113710324B (zh) 2025-02-14
EP3914358A1 (en) 2021-12-01
JP2022518282A (ja) 2022-03-14
WO2020154540A1 (en) 2020-07-30

Similar Documents

Publication Publication Date Title
US20230220081A1 (en) BISPECIFIC HETERODIMERIC FUSION PROTEINS CONTAINING IL-15 - IL-15Ralpha Fc-FUSION PROTEINS AND IMMUNE CHECKPOINT ANTIBODY FRAGMENTS
US11524991B2 (en) PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
TWI781098B (zh) 新穎的ｂ７-ｈ３-結合分子、其抗體藥物綴合物及其使用方法
CN107614013B (zh) 结合lag-3的分子和其使用方法
US12312411B2 (en) Anti-CD38 binding domains
JP2021072784A (ja) 抗ｃｄ３抗体、抗ｃｄ１２３抗体及びｃｄ３及び／又はｃｄ１２３に特異的に結合する二重特異性抗体
TW202231292A (zh) 用於調節分化簇ｉｖ及／或ｖｉｉｉ的經生物工程改造之ｔ細胞介導之免疫力、材料、及其他方法
EP3558368B1 (en) Adam9-binding molecules, and methods of use thereof
TW201627322A (zh) 抗-ｄｒ５抗體和包括其ｄｒ５-結合結構域的分子
CN110894240A (zh) 结合cd3和肿瘤抗原的异二聚体抗体
KR20220017892A (ko) T세포 매개 면역의 조절을 위한 물질 및 방법
WO2022056197A1 (en) Immune targeting molecules and uses thereof
CA3175134A1 (en) Materials and methods for modulating delta chain mediated immunity
TW202325735A (zh) 特異性結合ｃｄ４７及ｃｄ２０之雙特異性抗體及其用途
US20230374147A1 (en) Bcma/taci antigen-binding molecules
CN119546645A (zh) 特异性结合gucy2c和cd3的抗原结合分子及其医药用途
WO2023083298A1 (zh) 抗icosl抗体融合蛋白及用途
US20240239915A1 (en) Fc variant with high thermal stability and attenuated effector function
HK40128201A (en) Adam9-binding molecules, and methods of use thereof
EA052211B1 (ru) ВАРИАНТ Fc С ВЫСОКОЙ ТЕРМОСТАБИЛЬНОСТЬЮ И ОСЛАБЛЕННОЙ ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
HK40016088A (en) Adam9-binding molecules, and methods of use thereof
HK40016088B (en) Adam9-binding molecules, and methods of use thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240122

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241223

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241223

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241223

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250711

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20251112

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260318